Hypertrophic Cardiomyopathy Clinical Trial
Official title:
Taiwan Registry of Hypertrophic Cardiomyopathy (THIC) Research Synopsis
NCT number | NCT06381778 |
Other study ID # | 112006-E |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | February 6, 2023 |
Est. completion date | December 1, 2027 |
Hypertrophic cardiomyopathy (HCM) is hallmarked by the presence of left ventricular hypertrophy (LVH) and may present various symptoms including arrhythmia and heart failure. Mutations in the genes related to sarcomeric proteins and metabolic disorders are known causes of HCM. However, it remains required to further explore the prevalence of HCM in the context of Taiwanese' genetic background. Additionally, certain rare diseases that affect the heart, including Fabry disease, cardiac amyloidosis, may present LVH, which makes precise diagnosis among HCM and these diseases more challenging. In this TSOC multi-center registry, we aim to systematically evaluate the clinical, genetic, biochemical features,prevalence, and possible natural course of HCM and relevant rare diseases such as Fabry disease in Taiwan. In the meanwhile, we may also generate the specific "red-flag" signs of Fabry disease in Taiwan.
Status | Recruiting |
Enrollment | 2600 |
Est. completion date | December 1, 2027 |
Est. primary completion date | December 1, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years and older |
Eligibility | Inclusion Criteria: 1. Presence of left ventricular hypertrophy (LVH) on echo/CMRI: 2. maximal interventricular septal (IVST) and/or posterior wall thickness (PWT) =13 mm, 3. apical wall thickness =15 mm or a ratio of apical to basal LV wall thickness of = 1.3 at end-diastole, OR 4. maximal LV wall thickness = 15mm of ANY OTHER PART 5. Male and female adult age = 20 year-old 6. Patients willing to comply with and sign the informed consent Exclusion Criteria: 1. Patients refuse or unable to give informed consent 2. Patients unlikely to comply with the protocol or unable to understand the nature and possible consequences of the program 3. Co-arctation of the aorta, severe aortic stenosis, or severe LV pressure overload 4. Athletic heart 5. Non-compaction cardiomyopathy |
Country | Name | City | State |
---|---|---|---|
Taiwan | Far Eastern Memorial Hospital | New Taipei City |
Lead Sponsor | Collaborator |
---|---|
Far Eastern Memorial Hospital |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Death | Death | 1 year | |
Secondary | CV death | CV death | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03249272 -
Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve
|
Phase 4 | |
Recruiting |
NCT03846297 -
Optimisation of Decision Making for Defibrillator Implantation in Hypertrophic Cardiomyopathy
|
||
Completed |
NCT02806479 -
Hypertrophic Cardiomyopathy Pilot Study
|
||
Active, not recruiting |
NCT01225978 -
Refining Information Technology Support for Genetics in Medicine
|
N/A | |
Completed |
NCT00001632 -
Investigation Into the Use of Ultrasound Technique in the Evaluation of Heart Disease
|
N/A | |
Completed |
NCT00001534 -
Long Term Effects of Enalapril and Losartan on Genetic Heart Disease
|
N/A | |
Enrolling by invitation |
NCT04050579 -
OPIE in the Thin Interventricular Septum
|
N/A | |
Completed |
NCT03537183 -
Will Elevated Left Ventricle Filling Pressures Decrease by a Group Exercise Program in Patients With Hypertrophic CardioMyopathy?
|
N/A | |
Completed |
NCT02590809 -
Hypertrophic Cardiomyopathy Symptom Release by BX1514M
|
Phase 2 | |
Completed |
NCT00001396 -
Natural History and Results of Dual Chamber (DDD) Pacemaker Therapy of Children With Obstructive Hypertrophic Cardiomyop...
|
Phase 1 | |
Active, not recruiting |
NCT03723655 -
A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
|
Phase 2/Phase 3 | |
Completed |
NCT05135871 -
Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects
|
Phase 1 | |
Completed |
NCT04129905 -
Assessment of the Relations Between Endothelial and Venous Dysfunctions and Left Ventricular Obstruction in Genetic Hypertrophic Cardiomyopathies
|
N/A | |
Recruiting |
NCT03061994 -
Metabolomic Study of All-age Cardiomyopathy
|
N/A | |
Completed |
NCT02234336 -
Assessment of Wall Thickness in Hypertrophic Cardiomyopathy
|
||
Recruiting |
NCT00221832 -
Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases
|
N/A | |
Not yet recruiting |
NCT03706001 -
Efficacy of Psychotherapy for Improving Quality of Life in Patients With Hypertrophic Cardiomyopathy and Depression
|
N/A | |
Recruiting |
NCT06169358 -
Screening Patients With Fabry Disease in Patients With Hypertrophic Cardiomyopathy or Left Ventricular Hypertrophy
|
||
Not yet recruiting |
NCT04090437 -
HCM-AF Ablation With ACUTUS
|
N/A | |
Completed |
NCT04402268 -
Efficacy of Risk Assessment for Sudden Cardiac Death in Patients With Hypertrophic Cardiomyopathy
|